Company news
Novamind Inc news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
CSE Bulletin: Delist -Novamind Inc. (NM)
June 13, 2022
Novamind Obtains Final Order for Plan of Arrangement from the Supreme Court of British Columbia and Completes Acquisition by Numinus Wellness Inc.
June 10, 2022
Novamind Shareholders Approve Proposed Acquisition by Numinus
June 8, 2022
Novamind Announces New Patient Financing Options
June 2, 2022
Novamind Reports Fiscal Q3 2022 Financial Results and Operating Highlights
May 31, 2022
Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Shareholders of Novamind Vote FOR the Proposed Plan of Arrangement
May 27, 2022
Novamind Launches Group Psychedelic Treatment for Frontline Workers
May 19, 2022
Novamind Files Management Information Circular for Special Meeting of Shareholders and Announces Receipt of Interim Court Order for Plan of Arrangement
May 11, 2022
Novamind to Host Bionomics' PREVAIL Trial for Acute Treatment of Social Anxiety Disorder
May 10, 2022
Novamind Announces Virtual Group Health Coaching
May 2, 2022
Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research
April 12, 2022
Novamind Opens 8th Integrative Psychiatry Clinic
April 6, 2022
Novamind Partner to Acquire Specialized Ibogaine Group in Brazil
March 31, 2022
Novamind Expands Group Therapy Model
March 24, 2022
Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety
March 16, 2022
Novamind Grants Restricted Share Units
March 11, 2022
Novamind to Conduct Phase II Psilocybin Trial for Major Depressive Disorder
March 9, 2022
Novamind Reports Fiscal Q2 2022 Financial Results and Operating Highlights
March 1, 2022
Novamind Publishes Psychedelic Therapy Patient Case Studies
February 22, 2022
Novamind Advances Clinical Pilot for Frontline KAP
February 16, 2022
Novamind Participates in Alto Neuroscience Phase II Clinical Trial for MDD and PTSD
February 9, 2022
Novamind Appoints Prakash Gowd as Chief Operating Officer
February 8, 2022
Novamind Hosts Clinical Trial to Advance Ketamine Therapy for End-of-Life Patients
February 3, 2022
Novamind Announces Closing of CAD$5 Million Private Placement with Institutional Investor
January 25, 2022
Novamind Announces CAD$5 Million Private Placement with Institutional Investor
January 24, 2022
Novamind to Participate in Citi's Psychedelic Drug Video Call Series
January 20, 2022
Novamind Closes Arizona Acquisition
January 18, 2022
Novamind Hosts Pioneering Psychedelic Clinical Trial for Opioid Use Disorder
January 13, 2022
Novamind Unveils New Design Concept for Clinics
January 5, 2022
Novamind Signs Definitive Agreement to Acquire Arizona-based Clinics
December 23, 2021
Novamind Opens New Clinic with Specialized Focus on Substance Use Disorders
December 6, 2021
Novamind to Present at the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6
December 2, 2021
Novamind Partners with Uruguay-Based Bienstar Wellness to Develop Latin America's First Integrative Mental Health Clinic Network
December 1, 2021
Novamind Reports Fiscal Q1 Financial Results and Operating Highlights
November 29, 2021
Novamind Unveils New Logo and Invests in Unified Brand
November 24, 2021
Novamind Signs LOI to Acquire Two Mental Health Clinics in Arizona
November 16, 2021
Novamind to Present at International Summit on Psychedelic Therapies for Mental Illness
November 15, 2021
Novamind Enters New Lease Agreement Responding to Patient Demand
November 12, 2021
Novamind Secures Insurance Coverage for Ketamine from Four Major Payors
November 10, 2021
Novamind Announces Revocation of Cease Trade Order and Reinstatement of Trading
November 8, 2021
CSE Bulletin: Reinstatement - Novamind Inc. (NM)
November 8, 2021
Novamind Reports FY2021 Financial Results and Operating Highlights
November 5, 2021
CSE Bulletin: Suspensions (MMI, CNFA, VPN, NM, EXM)
November 4, 2021
Novamind Announces Cease Trade Order and Delay in Filing Annual Financial Statements
November 4, 2021
Novamind Unveils Stealth Mode Investment in Alto Neuroscience
October 22, 2021
Novamind Granted DEA Licenses for Psilocybin Research
October 13, 2021
Novamind to Present at LD Micro and KCSA Conferences
October 8, 2021
Novamind Launches New Psychedelic Palliative Care Program
October 7, 2021
Novamind to Deliver Keynote at PSYCH Investor Summit on October 7, 2021
October 4, 2021
Novamind Opens 6th Integrative Psychiatry Clinic, Adds 3rd Clinical Research Site
September 30, 2021
Decks
- Investor Presentation (November 2021)
Investor deck · 23 slides · Nov 29, 2021